Andrew W Roberts

Andrew W Roberts

UNVERIFIED PROFILE

Are you Andrew W Roberts?   Register this Author

Register author
Andrew W Roberts

Andrew W Roberts

Publications by authors named "Andrew W Roberts"

Are you Andrew W Roberts?   Register this Author

100Publications

3361Reads

27Profile Views

Concurrent Opioid and Benzodiazepine Prescriptions among Older Women Diagnosed with Breast Cancer.

J Natl Cancer Inst 2019 Oct 12. Epub 2019 Oct 12.

Department of Population Health and Department of Anesthesiology, University of Kansas Medical Center (KUMC); KU Cancer Center, KUMC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djz201DOI Listing
October 2019

Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma.

Br J Haematol 2019 Sep 24;186(6):e188-e191. Epub 2019 Jun 24.

Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16069DOI Listing
September 2019

Characteristics of New Opioid Use Among Medicare Beneficiaries: Identifying High-Risk Patterns.

J Manag Care Spec Pharm 2019 Sep;25(9):966-972

Department of Population Health Sciences, Duke University School of Medicine, and Duke Clinical Research Institute, Duke University, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18553/jmcp.2019.25.9.966DOI Listing
September 2019

Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?

Cancer Discov 2019 Aug;9(8):998-1000

Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-19-0575DOI Listing
August 2019

Reviewing state-mandated training requirements for naloxone-dispensing pharmacists.

Res Social Adm Pharm 2019 02 5;15(2):222-225. Epub 2018 Apr 5.

Division of Social and Administrative Sciences, University of Wisconsin-Madison School of Pharmacy, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.sapharm.2018.04.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173665PMC
February 2019

BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.

Cancer Cell 2018 12;34(6):879-891

The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, The University of Melbourne, Parkville, VIC 3010, Australia. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15356108183052
Publisher Site
http://dx.doi.org/10.1016/j.ccell.2018.11.004DOI Listing
December 2018

Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.

J Clin Oncol 2018 Oct 25:JCO1800359. Epub 2018 Oct 25.

Matthew S. Davids, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Gottfried von Keudell, Yale School of Medicine, New Haven, CT; Craig A. Portell, University of Virginia Health System, Charlottesville, VA; Jonathon B. Cohen, Winship Cancer Institute of Emory University, Atlanta, GA; David C. Fisher, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Francine Foss, Yale School of Medicine, New Haven, CT; Andrew W. Roberts, Royal Melbourne Hospital and University of Melbourne, Melbourne, Victoria, Australia; John F. Seymour, Royal Melbourne Hospital, Peter MacCallum Cancer Centre, and University of Melbourne, Melbourne, Victoria, Australia; Rod A. Humerickhouse, AbbVie, Chicago, IL; and Constantine S. Tam, Royal Melbourne Hospital, Peter MacCallum Cancer Centre, St Vincent's Hospital, and University of Melbourne, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.00359
Publisher Site
http://dx.doi.org/10.1200/JCO.18.00359DOI Listing
October 2018

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

J Clin Oncol 2018 07 1;36(19):1973-1980. Epub 2018 May 1.

Stephan Stilgenbauer and Johannes Bloehdorn, Ulm University, Ulm; Stephan Stilgenbauer, Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg; Barbara Eichhorst and Michael Hallek, Universitätsklinikum Köln, Köln; Johannes Schetelig, University Hospital, Technische Universität Dresden, Dresden; Clemens-Martin Wendtner, Klinikum Schwabing, Munich; Sebastian Böttcher, University Hospital of Schleswig-Holstein, Kiel, Germany; Peter Hillmen and Talha Munir, St James's University Hospital, Leeds; Anna Schuh, University of Oxford; Anna Schuh, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom; John F. Seymour, Peter MacCallum Cancer Centre; John F. Seymour, University of Melbourne; Andrew W. Roberts, Royal Melbourne Hospital, Parkville, Victoria; Stephen P. Mulligan, Royal North Shore Hospital, St Leonards, New South Wales, Australia; Steven Coutre, Stanford University Medical Center, Stanford, CA; Wojciech Jurczak, Jagiellonian University, Kraków, Poland; Sarit Assouline, McGill University, Montreal, Quebec, Canada; Matthew S. Davids, Dana-Farber Cancer Institute, Boston, MA; Lang Zhou, Ahmed Hamed Salem, Monali Desai, Brenda Chyla, Jennifer Arzt, Su Young Kim, Maria Verdugo, and Gary Gordon, AbbVie, North Chicago, IL; Ahmed Hamed Salem, Ain Shams University, Cairo, Egypt; and William G. Wierda, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.6840DOI Listing
July 2018

Buprenorphine Use and Spending for Opioid Use Disorder Treatment: Trends From 2003 to 2015.

Psychiatr Serv 2018 07 8;69(7):832-835. Epub 2018 May 8.

Dr. Roberts is with the Department of Preventive Medicine and Public Health and the Department of Anesthesiology, University of Kansas Medical Center, Kansas City. Dr. Saloner is with the Department of Health Policy and Management and the Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore. Dr. Dusetzina is with the Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1176/appi.ps.201700315DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028283PMC
July 2018

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.

N Engl J Med 2018 03;378(13):1211-1223

From the Peter MacCallum Cancer Centre, Melbourne, VIC (C.S.T., M.A.A., R.A., S.H., R.J.H., K.B., G.T., J.D.I., M.B., D.W., S.L., S.-J.D., M.A.D., J.F.S., A.W.R.), and the Victorian Comprehensive Cancer Centre (C.S.T., M.A.A., R.A., S.H., R.J.H., K.B., D.W., S.-J.D., M.A.D., J.F.S., A.W.R.), the Faculty of Medicine (C.S.T., R.J.H., S.-J.D., M.A.D., J.F.S., A.W.R.) and Centre for Cancer Research (S.-J.D., M.A.D.), University of Melbourne, the Department of Clinical Haematology and Bone Marrow Transplantation, the Royal Melbourne Hospital (C.S.T., M.A.A., K.B., J.F.S., A.W.R.), and the Division of Cancer and Haematology, Walter and Eliza Hall Institute of Medical Research (M.A.A., A.W.R.), Parkville, VIC - all in Australia; and the University Hospital of Schleswig-Holstein, Kiel (C.P.), and Klinikum der Universität, Ludwig-Maximilian University of Munich, Munich (M.D.) - both in Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1715519DOI Listing
March 2018

Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.

Clin Cancer Res 2017 Aug 18;23(16):4527-4533. Epub 2017 Jan 18.

Cancer and Haematology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-0955DOI Listing
August 2017

Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.

Blood 2017 06 4;129(25):3362-3370. Epub 2017 May 4.

Department of Clinical Haematology and Bone Marrow Transplantation, The Royal Melbourne Hospital, Parkville, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-01-763003DOI Listing
June 2017

Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.

J Clin Oncol 2017 May 3;35(15):1678-1685. Epub 2017 Apr 3.

Kenneth F. Bradstock and Warwick Benson, Westmead Hospital, University of Sydney; Arno Enno, Sandra Deveridge, and Philip Rowlings, Calvary Mater Newcastle Hospital, Newcastle; Luke Coyle, Royal North Shore Hospital, St Leonards; Campbell Tiley, Central Coast Health, Gosford; John Moore, St Vincent's Hospital; Mark Hertzberg, Prince of Wales Hospital, Sydney; Kimberly Cartwright, Wollongong Hospital, Wollongong; Ilona Cunningham, Concord Repatriation General Hospital, Concord; John Taper, Nepean Hospital, Penrith, New South Wales; Emma Link, Juliana Di Iulio, and John F. Seymour, Peter MacCallum Cancer Centre; Jeff Szer, Andrew Grigg, Andrew W. Roberts, and John F. Seymour, University of Melbourne; Andrew H. Wei, Monash University; Anthony Schwarer, Box Hill Hospital; Lynda Campbell, Victorian Cancer Cytogenetics Service, Melbourne; Jeff Szer, Andrew Grigg, and Andrew W. Roberts, Royal Melbourne Hospital, Parkville; Phillip Campbell, Deakin University School of Medicine, Geelong, Victoria; Paula Marlton, Anthony K. Mills, and Devinder Gill, University of Queensland, Brisbane, Queensland; Ray M. Lowenthal, University of Tasmania, Hobart, Tasmania; Ian D. Lewis and Peter Bardy, Royal Adelaide Hospital; Uwe Hahn, Queen Elizabeth Hospital, Adelaide, South Australia; James D'Rozario, The Canberra Hospital, Garran, Canberra, Australia Capital Territory; Gavin Cull, Sir Charles Gairdner Hospital; Michael F. Leahy, University of Western Australia; and Paul Cannell, Royal Perth Hospital, Perth, Western Australia, Australia.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.70.6374
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.70.6374DOI Listing
May 2017

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

J Clin Oncol 2017 Mar 17;35(8):826-833. Epub 2017 Jan 17.

Matthew S. Davids, Dana-Farber Cancer Institute, Boston, MA; Andrew W. Roberts, John F. Seymour, and Mary Ann Anderson, University of Melbourne; Andrew W. Roberts and Mary Ann Anderson, Royal Melbourne Hospital and Eliza Hall Institute of Medical Research; and John F. Seymour, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; John M. Pagel, Swedish Cancer Institute, Seattle, WA; Brad S. Kahl, Washington University Medical School, St Louis, MO; William G. Wierda, University of Texas MD Anderson Cancer Center, Houston, TX; Soham Puvvada, University of Arizona, Tucson, AZ; Thomas J. Kipps, University of California San Diego, San Diego, CA; Ahmed Hamed Salem, Martin Dunbar, Ming Zhu, Jeremy A. Ross, Lori Gressick, Monali Desai, Su Young Kim, Maria Verdugo, Rod A. Humerickhouse, and Gary B. Gordon, AbbVie, Chicago, IL; Ahmed Hamed Salem, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt; Franklin Peale, Genentech, South San Francisco, CA; John F. Gerecitano, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.4320DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455685PMC
March 2017

Targeting apoptotic pathways to treat lymphoid malignancies.

Authors:
Andrew W Roberts

Rinsho Ketsueki 2016;57(10):2054-2058

Department of Clinical Hematology and Bone Marrow Transplantation, The Royal Melbourne Hospital.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11406/rinketsu.57.2054DOI Listing
February 2017

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.

Lancet Oncol 2017 Feb 13;18(2):230-240. Epub 2017 Jan 13.

Victorian Comprehensive Cancer Centre, Parkville, Melbourne, VIC, Australia; Faculty of Medicine, University of Melbourne, Parkville, Melbourne, VIC, Australia; Department of Clinical Haematology and BMT, The Royal Melbourne Hospital, Parkville, Melbourne, VIC, Australia; Division of Cancer and Haematology, The Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30012-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5316338PMC
February 2017

Venetoclax: a primer.

Authors:
Andrew W Roberts

Blood Adv 2017 Feb 28;1(7):467. Epub 2017 Feb 28.

Division of Cancer and Haematology, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; Department of Clinical Haematology and Bone Marrow Transplantation, The Royal Melbourne Hospital, Parkville, VIC, Australia; Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, Australia; and Victorian Comprehensive Cancer Centre, Parkville, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2017000547DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738976PMC
February 2017

Reducing Opioid Misuse: Evaluation of a Medicaid Controlled Substance Lock-In Program.

J Pain 2016 11 4;17(11):1150-1155. Epub 2016 Aug 4.

UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpain.2016.07.003DOI Listing
November 2016

Lock-In Programs and the Opioid Epidemic: A Call for Evidence.

Am J Public Health 2016 Nov;106(11):1918-1919

Andrew W. Roberts is with the Department of Pharmacy Sciences, School of Pharmacy and Health Professions, and the Center for Health Services Research and Patient Safety, Creighton University, Omaha, NE. Walid F. Gellad is with the Center for Pharmaceutical Policy and Prescribing, University of Pittsburgh, and the VA Pittsburgh Healthcare System, Pittsburgh, PA. Asheley Cockrell Skinner is with the Duke Clinical Research Institute, Duke University, Durham, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2105/AJPH.2016.303404DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055780PMC
November 2016

Controlled Substance Lock-In Programs: Examining An Unintended Consequence Of A Prescription Drug Abuse Policy.

Health Aff (Millwood) 2016 10;35(10):1884-1892

Asheley C. Skinner is an associate professor at the Duke Clinical Research Institute, Duke University, in Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1377/hlthaff.2016.0355DOI Listing
October 2016

Targeting BCL-2-like Proteins to Kill Cancer Cells.

Trends Cancer 2016 08 30;2(8):443-460. Epub 2016 Jul 30.

The Walter and Eliza Hall Institute of Medical Research, Victoria 3052, Australia; Department of Medical Biology, University of Melbourne, Victoria 3052, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trecan.2016.07.001DOI Listing
August 2016

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.

Blood 2016 06 11;127(25):3215-24. Epub 2016 Apr 11.

Cancer and Haematology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, Australia; Department of Clinical Hematology and Bone Marrow Transplantation, The Royal Melbourne Hospital, Parkville, VIC, Australia;

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2016-01-68
Publisher Site
http://dx.doi.org/10.1182/blood-2016-01-688796DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4920022PMC
June 2016

New Agents to Treat Chronic Lymphocytic Leukemia.

N Engl J Med 2016 06;374(22):2186-7

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1602674DOI Listing
June 2016

Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia.

Semin Oncol 2016 Apr 6;43(2):274-9. Epub 2016 Feb 6.

University of Melbourne, Parkville, Victoria, Australia; Department of Clinical Haematology and BMT, Royal Melbourne Hospital, Parkville, Victoria, Australia; Cancer and Haematology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2016.02.014DOI Listing
April 2016

Current challenges and novel treatment strategies in double hit lymphomas.

Ther Adv Hematol 2016 Feb;7(1):52-64

Department of Clinical Hematology and Bone Marrow Transplant, Royal Melbourne Hospital, Parkville, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620715608091DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4713886PMC
February 2016

Targeting GM-CSF in inflammatory diseases.

Nat Rev Rheumatol 2016 Jan 3;12(1):37-48. Epub 2015 Dec 3.

Walter &Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria 3052, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrrheum.2015.161DOI Listing
January 2016

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

N Engl J Med 2016 Jan 6;374(4):311-22. Epub 2015 Dec 6.

From the Department of Clinical Haematology and the Bone Marrow Transplantation Unit, Royal Melbourne Hospital (A.W.R., M.A.A.), the Division of Cancer and Haematology, Walter and Eliza Hall Institute of Medical Research (A.W.R., M.A.A.), and the Victorian Comprehensive Cancer Centre (A.W.R., J.F.S.), Parkville, VIC, and the University of Melbourne (A.W.R., J.F.S.) and Peter MacCallum Cancer Centre (J.F.S.), Melbourne, VIC - all in Australia; Dana-Farber Cancer Institute, Boston (M.S.D., J.R.B.); the Swedish Medical Center, Seattle (J.M.P.); Washington University, St. Louis (B.S.K.); University of Arizona, Tucson (S.D.P.); Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.F.G.); University of California, San Diego, San Diego (T.J.K.); AbbVie, North Chicago, IL (L.G., S.W., M.D., M.Z., M.B.D., E.C., S.H.E., R.A.H.); and University of Texas M.D. Anderson Cancer Center, Houston (W.G.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1513257DOI Listing
January 2016

Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma.

Clin Cancer Res 2015 Dec 22;21(23):5222-34. Epub 2015 Jul 22.

Medical Oncology, Austin Health, Austin Hospital, Heidelberg, Victoria, Australia. Ludwig Institute for Cancer Research, Austin Branch, Heidelberg, Victoria, Australia. Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. School of Cancer Medicine, La Trobe University, Heidelberg, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0393DOI Listing
December 2015

BCL2 inhibition in double hit lymphoma.

Leuk Lymphoma 2015 Jul 21;56(7):1928-9. Epub 2015 Jan 21.

Division of Cancer and Haematology, The Walter and Eliza Hall Institute of Medical Research , Parkville , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.987769DOI Listing
July 2015

Aberrant actin depolymerization triggers the pyrin inflammasome and autoinflammatory disease that is dependent on IL-18, not IL-1β.

J Exp Med 2015 Jun 25;212(6):927-38. Epub 2015 May 25.

Division of Inflammation, Division of Cancer and Hematology, Division of Immunology, and ACRF Chemical Biology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia Department of Medical Biology, The University of Melbourne, Parkville, Victoria 3010, Australia

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1084/jem.20142384DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451132PMC
June 2015

Racial disparities across provider specialties in opioid prescriptions dispensed to medicaid beneficiaries with chronic noncancer pain.

Pain Med 2015 Apr 7;16(4):633-40. Epub 2014 Oct 7.

Injury Prevention Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pme.12555DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012901PMC
April 2015

Fas regulates neutrophil lifespan during viral and bacterial infection.

J Leukoc Biol 2015 Feb 3;97(2):321-6. Epub 2014 Dec 3.

*Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Biology and Faculty of Medicine, University of Melbourne, Parkville, Victoria, Australia; Department of Microbiology and Immunology, University of Melbourne at Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

View Article

Download full-text PDF

Source
http://www.jleukbio.org/content/early/2014/11/26/jlb.3AB1113
Web Search
http://www.jleukbio.org/cgi/doi/10.1189/jlb.3AB1113-594RR
Publisher Site
http://dx.doi.org/10.1189/jlb.3AB1113-594RRDOI Listing
February 2015

Validating the allogeneic stem cell transplantation disease risk index: sample size, follow-up, and local data are important.

Transplantation 2015 Jan;99(1):128-32

1 Department of Clinical Haematology and Bone Marrow Transplant Service, The Royal Melbourne Hospital, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/TP.0000000000000257DOI Listing
January 2015

Revisiting the washout period in the incident user study design: why 6-12 months may not be sufficient.

J Comp Eff Res 2015 Jan;4(1):27-35

Division of Pharmaceutical Outcomes & Policy, UNC Eshelman School of Pharmacy, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cer.14.53DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410733PMC
January 2015

The University of North Carolina's Health Care Pharmacy Assistance Progam.

N C Med J 2014 Sep-Oct;75(5):303-9

Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

View Article

Download full-text PDF

Source
November 2014

Patterns of medication adherence and health care utilization among patients with chronic disease who were enrolled in a pharmacy assistance program.

N C Med J 2014 Sep-Oct;75(5):310-8

Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

View Article

Download full-text PDF

Source
November 2014

North Carolina Medicaid recipient management lock-in program: the pharmacist's perspective.

J Manag Care Spec Pharm 2014 Nov;20(11):1122-9

University of North Carolina at Chapel Hill School of Medicine, 231 MacNider, 229B, CB 7225, Chapel Hill, NC 27599.

View Article

Download full-text PDF

Source
https://www.communitycarenc.org/media/publications/north-car
Web Search
http://dx.doi.org/10.18553/jmcp.2014.20.11.1122DOI Listing
November 2014

Assessing the present state and potential of Medicaid controlled substance lock-in programs.

J Manag Care Spec Pharm 2014 May;20(5):439-46c

UNC Eshelman School of Pharmacy, Campus Box 7573, Kerr Hall 2206, 301 Pharmacy Ln., Chapel Hill, NC 27599.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18553/jmcp.2014.20.5.439DOI Listing
May 2014

The effect of community pharmacy-based interventions on patient health outcomes: a systematic review.

Med Care Res Rev 2013 Jun 2;70(3):235-66. Epub 2012 Oct 2.

University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7573, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1077558712459215DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4958406PMC
June 2013

BH3 mimetic therapy: an emerging and promising approach to treating chronic lymphocytic leukemia.

Leuk Lymphoma 2013 May 1;54(5):909-11. Epub 2013 Feb 1.

Division of Cancer and Hematology, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2013.769223DOI Listing
May 2013

Mcl-1 and Bcl-x(L) coordinately regulate megakaryocyte survival.

Blood 2012 Jun 28;119(24):5850-8. Epub 2012 Feb 28.

Cancer and Hematology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2011-12-398834DOI Listing
June 2012

Towards a four-dimensional view of neutrophils.

Methods Mol Biol 2012 ;844:87-99

The Walter and Eliza Hall Institute, 1G Royal Parade, Parkville, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-61779-527-5_6DOI Listing
May 2012

IL-6 promotes acute and chronic inflammatory disease in the absence of SOCS3.

Immunol Cell Biol 2012 Jan 26;90(1):124-9. Epub 2011 Apr 26.

Department of Inflammation, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1038/icb.2011.29
Publisher Site
http://dx.doi.org/10.1038/icb.2011.29DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146962PMC
January 2012

Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies.

Pathology 2011 Oct;43(6):525-35

Divisions of Cancer & Haematology and Chemical Biology, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAT.0b013e32834b1b34DOI Listing
October 2011

Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets.

J Exp Med 2011 Sep 12;208(10):2017-31. Epub 2011 Sep 12.

Molecular Medicine Division, Cancer and Hematology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, Australia; Department of Medical Biology, The University of Melbourne, Parkville 3010, Australia.

View Article

Download full-text PDF

Source
http://www.jem.org/lookup/doi/10.1084/jem.20110750
Publisher Site
http://dx.doi.org/10.1084/jem.20110750DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3182050PMC
September 2011

Neutrophils require SHP1 to regulate IL-1β production and prevent inflammatory skin disease.

J Immunol 2011 Jan 15;186(2):1131-9. Epub 2010 Dec 15.

Cancer and Haematology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.

View Article

Download full-text PDF

Source
http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.1002702
Publisher Site
http://dx.doi.org/10.4049/jimmunol.1002702DOI Listing
January 2011

Structural basis for apoptosis inhibition by Epstein-Barr virus BHRF1.

PLoS Pathog 2010 Dec 23;6(12):e1001236. Epub 2010 Dec 23.

The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.ppat.1001236DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3009601PMC
December 2010

SOCS3 regulates graft-versus-host disease.

Blood 2010 Jul 30;116(2):287-96. Epub 2010 Apr 30.

The Queensland Institute of Medical Research, 300 Herston Rd., Brisbane, Queensland 4006, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2009-12-259598DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2910612PMC
July 2010

Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy.

Br J Haematol 2010 Jul 7;150(1):39-45. Epub 2010 May 7.

Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/j.1365-2141.2010.08162.x
Publisher Site
http://dx.doi.org/10.1111/j.1365-2141.2010.08162.xDOI Listing
July 2010

The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.

Mol Pharmacol 2010 Mar 28;77(3):483-94. Epub 2009 Dec 28.

Children's Cancer Institute Australia for Medical Research, University of New South Wales, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/mol.109.060780DOI Listing
March 2010

Regulation of multiple cytokine signalling pathways by SOCS3 is independent of SOCS2.

Growth Factors 2009 Dec;27(6):384-93

Division of Cancer and Haematology, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, 3050, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/08977190903210954DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412171PMC
December 2009

BH3-mimetics--the solution to chemoresistance?

Leuk Lymphoma 2009 Jul;50(7):1069-72

Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190903015644DOI Listing
July 2009

Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma.

Clin Cancer Res 2009 Jan;15(2):714-22

Clinical Haematology/Bone Marrow Transplant Department, The Alfred Hospital, Commercial Road, Prahran, Melbourne, Victoria, Australia 3181.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-1022DOI Listing
January 2009

A key role for G-CSF-induced neutrophil production and trafficking during inflammatory arthritis.

Blood 2008 Dec 29;112(13):5193-201. Epub 2008 Sep 29.

The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2008-02-139535DOI Listing
December 2008

In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas.

Proc Natl Acad Sci U S A 2008 Nov 11;105(46):17961-6. Epub 2008 Nov 11.

The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria 3050, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0809957105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2582212PMC
November 2008

Socs3 maintains the specificity of biological responses to cytokine signals during granulocyte and macrophage differentiation.

Exp Hematol 2008 Jul 8;36(7):786-98. Epub 2008 Apr 8.

Cancer and Haematology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2008.02.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2556307PMC
July 2008

Perturbed thymopoiesis in vitro in the absence of suppressor of cytokine signalling 1 and 3.

Mol Immunol 2008 May 5;45(10):2888-96. Epub 2008 Mar 5.

Signal Transduction Laboratory, St Vincent's Institute, 9 Princes Street, Fitzroy, Victoria 3065, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molimm.2008.01.024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4291229PMC
May 2008

Bortezomib: putting mantle cell lymphoma on death row.

Leuk Lymphoma 2008 Apr;49(4):657-8

Department of Malignant Haematology and Stem Cell Transplantion, The Alfred Hospital, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190801942378DOI Listing
April 2008

Mechanism of crosstalk inhibition of IL-6 signaling in response to LPS and TNFalpha.

Growth Factors 2007 Oct;25(5):319-28

Division of Cancer and Hematology, The Walter and Eliza Hall Institute of Medical Research, Parkville, Vic., Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/08977190701830151DOI Listing
October 2007

Programmed anuclear cell death delimits platelet life span.

Cell 2007 Mar;128(6):1173-86

Molecular Genetics of Cancer Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3050, Australia.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S009286740700196
Publisher Site
http://dx.doi.org/10.1016/j.cell.2007.01.037DOI Listing
March 2007